I-Mab(IMAB)

$2.88▼-0.02 (-0.69%)

Chart

I-Mab(IMAB)

NASDAQ

$2.88▼-0.02 (-0.69%)

Chart Studio

IMAB(IMAB)

IMAB

Overview Intelligence Chart History Fundmntls TTM Earnings Growth Analysts News Financials Insiders Institl.DCF Peers

IMAB 50 articles

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

globenewswire.com·Oct 29

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

prnewswire.com·Oct 28

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

prnewswire.com·Oct 23

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

globenewswire.com·Oct 22

I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript

seekingalpha.com·Oct 17

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

globenewswire.com·Oct 16

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

globenewswire.com·Oct 14

I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know

zacks.com·Oct 10

What Makes IMab (IMAB) a New Buy Stock

zacks.com·Oct 6

I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market

seekingalpha.com·Sep 10

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

zacks.com·Aug 28

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

globenewswire.com·Aug 25

I-Mab to Participate in September Investor Conferences

globenewswire.com·Aug 21

Everest Medicines Expands Strategic Investment in I-MAB

prnewswire.com·Aug 1

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

globenewswire.com·Aug 1

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

globenewswire.com·Jul 17

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

globenewswire.com·Jul 2

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

globenewswire.com·Jun 30

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

globenewswire.com·Jun 26

I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross

zacks.com·Jun 11

I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?

zacks.com·Jun 6

I-Mab to Present at Jefferies Global Healthcare Conference

globenewswire.com·May 20

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)

zacks.com·Apr 14

After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)

zacks.com·Apr 11

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

globenewswire.com·Mar 21

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

globenewswire.com·Mar 7

I-Mab to Participate in Leerink Partners Global Healthcare Conference

globenewswire.com·Feb 18

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

globenewswire.com·Feb 4

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

prnewswire.com·Jan 8

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

prnewswire.com·Jan 6

I-Mab to Participate at the Piper Sandler Healthcare Conference

prnewswire.com·Nov 21

I-Mab Reports Third Quarter 2024 Results

prnewswire.com·Nov 14

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

prnewswire.com·Nov 6

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

prnewswire.com·Oct 31

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

prnewswire.com·Oct 30

I-Mab to Participate at the Truist Securities BioPharma Symposium

prnewswire.com·Oct 28

IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade

zacks.com·Oct 9

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

prnewswire.com·Sep 16

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

prnewswire.com·Sep 10

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

prnewswire.com·Aug 28

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

prnewswire.com·Aug 26

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

prnewswire.com·Aug 14

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

prnewswire.com·Aug 7

I-Mab Announces Leadership Transitions

prnewswire.com·Jul 15

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

prnewswire.com·Jun 5

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

globenewswire.com·May 23

I-Mab to Participate at the Jefferies Global Healthcare Conference

prnewswire.com·May 22

I-MAB Filed 2023 Annual Report on Form 20-F

prnewswire.com·Apr 30

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

prnewswire.com·Apr 5

I-Mab Announces Closing of the Divestiture of Business Operations in China

prnewswire.com·Apr 2

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance